Application Fees JACIE Board Related Publications The Joint Accreditation Committee-ISCT & EBMT is a non-profit body established in 1998 for the purposes of assessment and accreditation in the field of haematopoietic stem cell (HSC) transplantation. JACIE's primary aim is to promote high quality patient care and laboratory performance in haematopoietic stem cell collection, processing and transplantation centres through an internationally recognised system of accreditation. The Committee was founded by the European Group for Blood and Marrow Transplantation (EBMT) and the International Society for Cellular Therapy (ISCT), the two leading scientific organisations involved with HSC transplantation in Europe. JACIE in collaboration with FACT has established standards for the provision of quality medical and laboratory practice in HSC transplantation; conducts inspections, and accredits programmes that will encourage health institutions and facilities performing HSC transplantation to voluntarily meet these standards; and recognises compliance with standards by issuance of Certificates of Accreditation. Accreditation is the means by which a centre can demonstrate that it is performing to a required level of practice in accordance with agreed standards of excellence. Essentially it allows a centre to certify that it operates an effective quality management system. A quality management system is a mechanism to ensure that procedures are being carried out in line with agreed standards with full participation by all staff members. In a cell transplant programme, this ensures that the clinical, collection and laboratory units are all working together to achieve excellent communication, effective common work practices and increased guarantees for patients. It is a means of rapidly identifying errors or accidents and resolving them so that the possibility of repetition is minimised. It assists in training and clearly identifies the roles and responsibilities of all staff. Once the required level of quality has been achieved, the remaining challenge is to maintain this standard of practice. With a working quality management system in place and adequate resources, the fundamental elements necessary to sustain the programme are continued staff commitment and vigilance. The JACIE Accreditation Programme was supported in 2004 by the European Commission under the Public Health Programme 2003-2008. Fees The current fees are detailed in the document "Accreditation Fees [DATE] - Terms & Conditions.pdf", available in the Document Centre on the left-hand side of this web page. JACIE Board Executive Committee President: Jane Apperley (EBMT) Past-President: Ineke Slaper-Cortenbach (ISCT) Vice-President: Christian Chabannon (ISCT Europe) Medical Director: Derwood Pamphilon Accreditation Committee chair: Christiane Vermylen National & Sectoral Representatives Related publications Sistemas de gestión de la Calidad en al ámbito sanitario. 5ª parte. M. Castella. Forum calidad, ISSN 1139-5567, Año nº 20, Nº 191, 2008 , pags. 58-63 Expérience de mise en place d'une démarche qualité basée sur le référentiel JACIE au sein de la Fédération de greffe de moelle et de thérapie cellulaire d'Auvergne. RISQUES ET QUALITE; 5, 1; 1767-3445; 31-41. Le programme JACIE (Joint Accreditation Committee of ISCT-Europe and EBMT).Pourquoi? Pour qui? Catherine Boccaccio et al. Hématologie 2008 ; 14 (1) : 48-55 JACIE accreditation in paediatric haemopoietic SCT. J M Cornish. Bone Marrow Transplant 2008 42: S82-S86; 10.1038/bmt.2008.290 Standards for the Terminology and Labeling of Cellular Therapy Products. Paul Ashford et al. Transfusion Volume 47 Issue 7 Page 1319-1327. Current status of JACIE accreditation in Europe: a special report from the Joint Accreditation Committee of the ISCT and the EBMT (JACIE). D. Samson et al. Bone Marrow Transplant (2007) 39, 133–141. ASBMT White Paper on Measurement of Quality Outcomes. Committee on Hematopoietic Cell Therapy Quality Outcomes. Biology of Blood and Marrow Transplantation 12:594-597 (2006). American Society for Blood and Marrow Transplantation. What Is Quality in a Transplant Program? C. Fred LeMaistre, Fausto R. Loberiza, Jr. Biology of Blood and Marrow Transplantation 11:241-246 (2005) Who will regulate the regulators? J M Goldman. Bone Marrow Transplantation (2004) 34, 1013-1014 Implementation of the JACIE standards for a haematopoietic progenitor cell transplantation programme: a cost analysis. Zahnd D, Leibundgut K, Zenhausern R, Pabst T, Fontana S, Schneider R, Tobler A, Zwicky C. Bone Marrow Transplant. 2004 Nov;34(10):847-53. Just Another Cost Increasing Exercise (JACIE)? Apperley J. Bone Marrow Transplant. 2004 Nov;34(10):835-8. Real-time process/quality control for HPC processing. Arpagaus M, Leibundgut EO, Zbaren K, Brunold C, Ischi E, Tobler A, Zwicky C. Cytotherapy. 2004;6(5):505-13. Stem-cell harvesting and manipulation. D. Pamphilon. Vox Sanguinis Volume 87 Issue s1 Page 20 - June 2004 Impact of regulations on translational research in cell and gene therapy: the US experience. Raphaël F. Rousseau, Adrian P. Gee. (French). Bulletin du Cancer. Number 91, volume 3, 239-47, MARS 2004 Outbreaks of infectious diseases in stem cell transplant units: a silent cause of death for patients and transplant programmes. McCann S, Byrne JL, Rovira M, Shaw P, Ribaud P, Sica S, Volin L, Olavarria E, Mackinnon S, Trabasso P, VanLint MT, Ljungman P, Ward K, Browne P, Gratwohl A, Widmer AF, Cordonnier C; Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant. 2004 Mar;33(5):519-29. Quality issues in stem cell and immunotherapy laboratories. L. Smith and M. W. Lowdell. Transfusion Medicine Volume 13 Issue 6 Page 417 - December 2003 JACIE accreditation in Europe moves ahead. Kvalheim G, Gratwohl A, Urbano-Ispizua A; JACIE national representatives.Cytotherapy. 2003;5(4):306-8. The role and activities of the ISCT Regulatory Affairs Committee. Kelley L Cytotherapy. 2003;5(4):279-83 Development and operation of a quality assurance system for devaitions from standard operating procedures in a clinical cell therapy laboratory.McKenna D, Kadidlo D, Dumstad D, McCullough J. Cytotherapy 2003, 5: 314-322. Voluntary accreditation of cellular therapies: Foundation for the Accreditation of Cellular Therapy (FACT). Warkentin PI; Foundation for the Accreditation of Cellular Therapy. Cytotherapy. 2003;5(4):299-305. Current regulatory issues in cell and tissue therapy. Burger, SR. Cytotherapy. 2003;5(4):289-98. Donor-derived hematopoietic stem cells in organ transplantation: technical aspects and hurdles yet to be cleared. Herve, Patrick. Transplantation. 75(9) Supplement:55S-57S, May 15, 2003. Validation of Haematopoietic Progenitor Cell Processing. Arpagaus M, Oppliger Leibundgut E, Zbären K, et al. Schweiz Med Forum 2003; (suppl.12): 67S (abstr. P423). Implementation of the JACIE-standards for hematopoietic stem cell transplantation at the university hospital of Bern, Switzerland Zahnd D., Schneider R., Tobler A., Zwicky C. ISQua Conference, Paris 8 November, 2002. Oral Presentation 231 Regulation of hematopoietic stem cell processing and transplantation. Rowley SD. Int J Hematol. 2002 Apr;75(3):237-45. A European reference protocol for quality assessment and clinical validation of autologous haematopoietic blood progenitor and stem cell grafts. Serke S, Johnsen HE. Bone Marrow Transplant. 2001 Mar;27(5):463-70. Regulatory aspects and accreditation of the clinical use of hematopoietic progenitor cells in Europe. Kvalheim G, Urbano-Ispizua A, Gratwohl A. J Biol Regul Homeost Agents. 2001 Jan-Mar;15(1):79-80. Standards of stem cell transplantation: Part I: the accreditation of paediatric stem cell transplantation centres within the EBMT; Part II: intensive care units in paediatric stem cell transplantation; Part III: informed consent and sibling donor issues. Cornish J, Peters C. Bone Marrow Transplant 2001; 28 (suppl. 1):S4-S5. FAHCT accreditation: common deficiencies during on-site inspections. Warkentin PI, Nick L, Shpall EJ. Cytotherapy. 2000;2(3):213-20. FAHCT-JACIE workshop on accreditation for blood and marrow progenitor cell processing, collection and transplantation, Barcelona, Spain. Kvalheim G, Urbano-Ispizua, Gratwohl A. Cytotherapy 2000; 2: 223-224. Can improving quality decrease hospital costs? Jarlier A, Charvet-Protat S. Int J Qual Health Care. 2000 Apr;12(2):125-31 EBMT and ISHAGE-Europe create a foundation for inspection and accreditation in Europe. Editorial. Kvalheim G. Cytotherapy 1999; 1: 363-364. Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT) response to FDA (Docket no. 97N-0068). FAHCT Board of Directors. Shpall EJ. J Hematother. 1997 Aug;6(4):287-9. as follows: